Radar · Industry landscape · Canada
Life Sciences Landscape of Canada
1,979 Life Sciences companies in Canada, in one picture: who is hiring, who is raising money, who founded them, where they are based, what the news is about, which skills employers want and where the research is going. Updated August 2026.
1,979companies tracked
$38.7Bdisclosed funding
148hiring right now
1,757events · 24 months
25,872news articles · 12 months
Who leads Life Sciences in Canada
Shows the top‑ranked life‑science firms in Canada by size, funding, hiring activity and media coverage, noting 1,979 tracked companies, 148 currently hiring and 524 with disclosed funding rounds.
open roles
Hiring now
ranked by live open roles
- 01
Fresh Prep11last posted Jun 2026
- 02
Dynacare11last posted Jun 2026
- 03
Amico11last posted Jun 2026
- 04
Bausch Health10last posted Jun 2026
- 05
Optel Group9last posted Jul 2026
- 06
Able Innovations8last posted Jun 2026
- 07
Sonic Incytes8last posted May 2026
- 08
Kinova8last posted May 2026
148 companies hiring · 1 posted in the last 30 days
disclosed funding
Most funded
disclosed totals, all rounds
- 01
- 02
Kardium$471.4MSeries C · Jul 2025
- 03
Milestone Pharmaceuticals$318.7MPost IPO · Mar 2023
- 04
Liminal BioSciences$306.6MPost IPO · Oct 2020
- 05
Resverlogix$301.3MPost IPO · Oct 2020
- 06
Virogin Biotech$281MSeries D · Sep 2021
- 07
ProMIS Neurosciences$247.3MPost IPO · Jan 2026
- 08
Abcellera Biologics$239.1MPost IPO · Jun 2021
524 companies with disclosed rounds · $38.7B total
revenue
Revenue leaders
official filings first, else latest snapshot
- 01
- 02
Arbutus Bio$179.1MFY2015 filing
- 03
Aurinia Pharmaceuticals$77.7MFY2024 filing
- 04
- 05
Sunshine Biopharma$8.1MFY2026 filing
- 06
Zymeworks$5.4MFY2022 filing
- 07
Profound Medical$5.1MFY2025 filing
- 08
BIONIK$1.8MFY2020 filing
16 companies with a revenue figure
headcount
Largest teams
ranked by tracked headcount
- 01
Patterson Dental6,772tracked employees
- 02
- 03
- 04
- 05
Actlabs452tracked employees
- 06
- 07
Benchsci426tracked employees
- 08
Ocean Nutrition Canada415tracked employees
203 companies with headcount data
share of events
Share of voice
share of all tracked sector news events, 24 months
- 01
- 02
- 03
- 04
Oncolytics Biotech3.0%75 tracked events
- 05
- 06
eupraxia pharmaceuticals2.6%64 tracked events
- 07
ESSA Pharma2.3%56 tracked events
- 08
Microbix2.2%53 tracked events
2,465 tracked events across 225 companies
articles
In the news
Prism news coverage, last 12 months
- 01
Eli278articles in the window
- 02
- 03
- 04
Clearmind56articles in the window
- 05
Xenon Pharmaceuticals48articles in the window
- 06
Kane Biotech47articles in the window
- 07
Hemostemix43articles in the window
- 08
Cardiol Therapeutics40articles in the window
134 of these companies drew sector coverage in the window
Radar
See all 1,979 Life Sciences companies in Canada
Filter by funding, headcount, hiring and location, and export the list.
How the Life Sciences ecosystem in Canada grew, 2016–2025
Displays the annual count of new life‑science companies founded from 2016‑2025, highlighting a peak of 129 startups in 2020 and only 7 in 2025.
Companies founded / year
new Life Sciences companies in Canada
20162025
peak 129 in 2020
Companies raising / year
with a disclosed round that year
20162025
peak 120 in 2019
Disclosed funding / year
sum of disclosed rounds (USD)
20162025
peak $8.2B in 2018
Where Life Sciences companies in Canada are based
Hub 01
Toronto
395 Life Sciences companies
36% of the Life Sciences companies across these hubs
395companies
$3.2Bdisclosed funding
29hiring now
Hub 02
Vancouver
234 Life Sciences companies
21% of the Life Sciences companies across these hubs
234companies
$2.5Bdisclosed funding
18hiring now
Hub 03
Montreal
186 Life Sciences companies
17% of the Life Sciences companies across these hubs
186companies
$1.9Bdisclosed funding
19hiring now
Hub 04
Calgary
75 Life Sciences companies
7% of the Life Sciences companies across these hubs
75companies
$632.3Mdisclosed funding
4hiring now
Hub 05
Mississauga
54 Life Sciences companies
5% of the Life Sciences companies across these hubs
54companies
$567.5Mdisclosed funding
3hiring now
Hub 06
Edmonton
53 Life Sciences companies
5% of the Life Sciences companies across these hubs
53companies
$301Mdisclosed funding
6hiring now
Hub 07
Ottawa
52 Life Sciences companies
5% of the Life Sciences companies across these hubs
52companies
$158.5Mdisclosed funding
3hiring now
Hub 08
Quebec City
48 Life Sciences companies
4% of the Life Sciences companies across these hubs
48companies
$434.1Mdisclosed funding
3hiring now
The Life Sciences market map of Canada: what these companies actually do
Breaks down the product categories and revenue models of the sector, with enterprise tech (1,273 firms) and medical devices (470) as the largest sub‑categories, and physical commerce (976) as the most common revenue model.
- Enterprise Tech1,273 companies · $36.6B raised · 119 hiring
- Medical Devices470 companies · $2.8B raised · 42 hiring
- Healthtech401 companies · $1.5B raised · 37 hiring
- Biopharmaceuticals369 companies · $32.9B raised · 25 hiring
- Consumer Digital338 companies · $775.3M raised · 10 hiring
- Enterprise Software288 companies · $1.7B raised · 25 hiring
- Deep Tech283 companies · $2B raised · 26 hiring
- Nutritional Formula116 companies · $154.6M raised · 6 hiring
- SaaS106 companies · $664M raised · 11 hiring
- Healthtech SaaS90 companies · $652.7M raised · 9 hiring
- In Vitro Diagnostics84 companies · $511.6M raised · 5 hiring
- Chronic Disease Management72 companies · $315.8M raised · 7 hiring
Monetization
How Life Sciences companies make money
How many companies earn revenue each way. Plenty use more than one model, so the counts add up to more than the sector.
Physical Commerce976
E-Commerce - Product892
Subscription582
Fee-For-Service275
Commission on Transaction59
Advertising42
E-Commerce - Service25
Licensing3
Funding, M&A and the deals moving Life Sciences in Canada
Earnings 450Funding 392Leadership 276M&A 131Announcement 123Contracts 87Board Updates 79Regulatory 72IPO 44Assets 37
- FundingOcumetics Technology Corp. (“Ocumetics” or the “Corporation”) announces that it proposes to complete a private placement (the “Offering”) of up to 2,800,000 units of the Corporation (“Units”) at a price of $0.55 per Unit for gross proceeds of up to $1,540,000.2026-04-29
- FundingPreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 40,000,000 units (each, a "Unit") in the capital of the Company at a price of $0.025 per Unit for gross proceeds of up to $1,000,000.2026-04-21
- FundingViewsML raised $4.9M seed round for virtual biomarker staining.2026-04-20
- FundingThe $CAN 2.66 million financing, in conjunction with the previously announced $CAN 1.1 million equity financing completed on March 10th, strengthens our balance sheet and provides the Company with additional capital to execute on its strategic initiatives.2026-04-10
- M&AOrganon decided to sell its JADA post-partum haemorrhage (PPH) treatment system to Laborie Medical for up to $465 million.2026-04-10
- FundingLobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is pleased to announce a non-brokered private placement offering of 14,615,384 common shares in the capital of the Company ("Common Shares") at a price of $0.065 per Common Share, for aggregate gross proceeds of approximately $950,000 (the "Private Placement").2026-04-10
- FundingVoxCell BioInnovation in Victoria: $110,0002026-04-07
- M&AAurinia Pharmaceuticals has entered into a definitive agreement to acquire Kezar Life Sciences.2026-04-05
- M&AVenus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the successful completion by affiliates of Madryn Asset Management, LP (“Madryn”) of a short-form merger transaction, pursuant to which 100% ownership of the Company’s common stock is now consolidated under funds managed by Madryn (the “Short-form Merger”).2026-04-01
- FundingRENAISSANCE BIOSCIENCE | Secures a $550,000 Genome BC grant for a 24-month project to build a proprietary wild yeast discovery platform in partnership with the University of British Columbia.2026-03-12
Mergers and acquisitions
Deals from the last 24 months where a Life Sciences company in Canada was the buyer or the one bought, newest first. “Undisclosed” means the price was never published — not that the deal was worth nothing.
| Acquirer | Target | Deal value | Status | Date |
|---|---|---|---|---|
| undisclosed | Announced | 2026-04-13 | ||
| $465M | — | 2026-04-10 | ||
| JADA post-partum haemorrhage treatment system | $465M | Completed | 2026-04-10 | |
| undisclosed | Announced | 2026-04-02 | ||
| undisclosed | Announced | 2026-04-01 | ||
| undisclosed | Completed | 2026-03-30 |
Who is listing, hiring leaders, launching and winning work
Details specific corporate milestones such as IPO filings, leadership changes, product launches and contract wins for the tracked companies.
IPO pipeline
26 companies listed or filing · last 24 months
Satellos BioscienceIPO · Nasdaq Global Market · MSLE · 2 reportsFeb 2026
enGeneFollow-on Offering · NASDAQ · ENGN · 1 reportNov 2025
BionxtOTCQB · BNXTF · 1 reportSep 2025
ConaviFollow-on Offering · TSX Venture Exchange · CNVI · 2 reportsMar 2025
Allelix BiopharmaceuticalsIPO · 1 reportFeb 2025
Leadership moves
76 tracked people moves · last 12 months
AlphaCognitionBethany Sensenig · Appointment → Board of DirectorsApr 2026
Telo GenomicsJohn Farlinger · Appointment → Chief Executive Officer and ChairmanApr 2026
Product launches
tracked launches · last 12 months
Nextleaf SolutionsYard Cannabis (Recreational cannabis brand)Feb 2026
VitalityVitality AI (Platform)Nov 2025
Contract wins
34 customer wins · last 24 months
Entheon Biomedicalwon aloe financeJan 2026
BioHarvest Scienceswon Nutrition and ingredients organizationDec 2025
Workforce actions
7 companies cutting roles · last 24 months
Repare Therapeutics~75% of workforce reported · cost reductionFeb 2025
QLT~115 roles reported · cost reductionFeb 2025
Stressgen Biotechnologies~64 roles reported · cost reductionFeb 2025
Regulatory & litigation
65 regulatory events · 15 tracked suits · 24 months
VentriPointsubmitted for approval — China\'s National Medical Products AdministrationApr 2026
XORTX Pharmaapproved for share consolidation — TSX Venture Exchange and Nasdaq Stock ExchangeApr 2026- KAOS Capital Ltd, Adam Arviv v psyenceshareholder claim alleging improper and oppressive actions · SettledFeb 2026
- KAOS Capital Ltd v Psyence Biomedshareholder claim · SettledFeb 2026
Earnings pulse
companies reporting results · last 24 months
70 companies reporting466 company-quarters trackedbeat 43miss 48in line 9
Half of these companies grew revenue faster than +24.0%, half slower.
Who is building Life Sciences in Canada
Profiles 1,210 founders and CEOs across 931 firms, noting the University of Toronto as the most common alma mater (100 alumni) and Microsoft as the top prior employer (2 founders).
Founders and chief executives12 of 1,210, from the best-funded companies on this page
Ex-Microsoft Research · University of Manitoba MSc 1993, University of Toronto PhD 1997
NYU Langone Medical Center. American University of Beirut BS 2001, The University of Texas Southwestern Medical Center PhD 2005
University of Buea 2006, McMaster University MSc 2012, University of Toronto PhD 2019
Ex-Sanofi Pasteur, Roche. University St.Gallen MBA
Abdera Therapeutics, LifeSciences BC, ex-adMare BioInnovations. Harvard University AB 1989, McGill University PhD 1998
Ex-ABK Biomedical, Ellex, President and CEO ReShape Medical. Saint Joseph's University BS, Marketing 1992
Tela Bio, ex-Vesper Medical, ex-Intact Vascular, university of pennsylvania, 1970
Ex-Founder-Caprion Pharmaceuticals, CEO-Clementia Pharmaceuticals, Cepmed, Bioconcept · McGill University PhD 1992
University of Toronto PhD 2008
Where the founders studied
alma mater on record for 233 of 1,210 founders
University of Toronto100
University of Waterloo31
McGill University18
The University of British Columbia17
Harvard University12
McMaster University9
Queen's University9
Massachusetts Institute of Technology8
Where they worked before
a previous employer on record for 5 of 1,210 founders
Microsoft2
Cisco1
McKinsey1
Facebook1
Goldman Sachs1
Founders flagged as repeat founders
of 1,084 founders with a profile on this page
3
carry a repeat-founder flag
- flagged as repeat founders3
- no repeat-founder flag1,081
Radar
Look up the people behind Life Sciences companies in Canada
Search founders, executives and operators by company, role and location.
Who funds Life Sciences in Canada
Summarizes 1,531 funding rounds since 2016 from 749 investors, with the typical round size of $1.6 million.
| Investor · most active investors since 2016 | Rounds | Led | Latest |
|---|---|---|---|
| BDC | 31 | 7 | Mar 2026 |
| Amplitude | 22 | 12 | Mar 2026 |
| Fonds de solidarite FTQ | 22 | 5 | Mar 2026 |
| Invest Quebec | 20 | 9 | Mar 2026 |
| Accelerator Centre | 19 | 15 | Sep 2025 |
| Lumira Ventures | 17 | 9 | Mar 2026 |
| Anges Quebec | 17 | 5 | Jun 2024 |
| National Research Council Canada | 16 | — | May 2025 |
| Canadian Space Agency | 15 | — | Nov 2021 |
| Y Combinator | 14 | 7 | Jan 2023 |
Stage mix · rounds since 2016
Seed & Angel375
Series A–B251
Series C+ / PE37
Grants, debt & other868
The typical round is $1.6M — half were bigger, half smaller.
The biggest Life Sciences funding rounds in Canada
Highlights the largest disclosed round—Kardium’s $250 million Series C—and lists ten other major recent funding events.
| Company | Round | Size | When | Backers |
|---|---|---|---|---|
| Series Cmega-round | $250M | Jul 2025 | Janus Henderson Investors, Qatar Investment Authority, Piper Sandler +5 more | |
| Series C | $180M | Jul 2021 | SoftBank Vision Fund, CPP Investments, Alexandria +5 more | |
| Series A | $150M | Aug 2024 | Versant Ventures, Novartis | |
| Series D | $127M | Sep 2021 | Shenzhen Capital Group, Panlin Capital, GF Securities +4 more | |
| Series A | $119.8M | Jan 2024 | Novo Holdings, Arkin Holdings, Mitsui Global Investment +4 more | |
| Series B | $116.3M | Dec 2020 | Fidelity Investments, T. Rowe Price | |
| Series D | $114.4M | Dec 2019 | Guoxin Capital, SBCVC, Langmafeng Venture Capital +1 more | |
| Series B | $110M | Apr 2023 | VenBio, Versant Ventures, Viking Global Investors +5 more | |
| Series B | $105M | Mar 2020 | Orbimed, DCVC, Viking Global Investors +5 more | |
| Series B | $105M | Apr 2019 | Varian Medical Systems, Perceptive Advisors, Orbimed +9 more |
Venture round sizes · 2023–2025
<$1M47
$1–10M57
$10–50M37
$50–250M6
>$250M1
148 venture rounds with a disclosed amount in the window.
Fresh cheques · last 6 months
Seed$366kMay 2026
Seed$366kMay 2026
Seed$366kMay 2026
Seed$45kMay 2026
Series B$12MApr 2026
Seed$3.6MApr 2026
Post IPO$693kApr 2026
Grant (prize money)undisclosedApr 2026
What the news says about Life Sciences in Canada
Counts 25,872 news articles in the last year, most frequently covering COVID‑19 vaccine work, oncology advances, drug pricing, and rare‑disease therapies.
News volume
Life Sciences coverage across Canada · articles per quarter
2021Q22026Q1
peak 22,276 in 2025Q1 · 25,872 articles in the last 12 tracked months
Tone of coverage
share of articles by dominant sentiment (positive / neutral / negative)
202120232025
Positive-tone share moved 78% → 83%, negative 21% → 15% across 2021–2025.
What the coverage is about
The subjects that dominate Life Sciences news in Canada. The arrow shows whether each one is being written about more or less than a year ago.
- Covid-19 vaccine development and efficacy trials4,865▲+352%
- Oncology and targeted therapy advancements3,669▼-30%
- Drug pricing and reimbursement strategies3,408▲+13%
- Rare disease therapies and orphan drugs3,010▼-46%
- Biotech startups and venture capital funding2,861▲+102%
- Covid-19 vaccination campaigns and rollout strategies2,821▲+611%
- Generic drug development and market trends2,326▲+15%
- Vaccine research and production methods2,296→-8%
- Gene therapy and crispr technologies2,126▼-37%
- Pharmaceutical marketing and sales strategies2,022▲+30%
Most-covered companies · last 12 months
- 278
- 163
- 61
- 56
- 48
- 47
- 43
- 40
- 37
- 33
134 Life Sciences companies here were named in the news over this period.
Prism
Watch Life Sciences coverage in Canada as it happens
Prism follows these subjects story by story — which companies are named, what is said about them and how the tone moves.
Momentum
The words getting louder — and quieter
Which terms are showing up in more stories than a year ago, and which are fading. The percentage is the change in how many articles mention them.
angel investors+181%asset acquisition+191%early-stage investment+211%vaccine candidates+357%vaccine trials+375%vaccination campaigns+545%vaccine immunogenicity+372%mass vaccination sites+789%vaccination coverage+392%vaccine effectiveness study+359%
biosimilar approval-49%copa libertadores-100%biosimilar market entry-37%gene therapy rare diseases-56%biosimilar efficacy-44%
The pressures the press keeps returning to
Three recurring angles in Canada Life Sciences coverage, and whether each is getting more attention year on year (through 2025).
Regulatory Risk ▲ rising
44,617 articles touch this dimension · 39.2% critical tone
20212025
signals: vaccine candidates, vaccine trials, vaccine immunogenicity
Funding Momentum ▲ rising
16,107 articles touch this dimension · 40.1% critical tone
20212025
signals: angel investors, asset acquisition, early-stage investment
Growth ▲ rising
31,705 articles touch this dimension · 31.6% critical tone
20212025
signals: earnings report, quarterly results, biosimilar market entry
Life Sciences jobs in Canada: who is hiring and what they ask for
Reports 1,512 job postings from 111 employers in the past year, with median advertised salary of $37 k and top skills including phlebotomy, Excel and Outlook.
1,512postings · last 12 months
2,834postings tracked overall
111employers advertising
$37kmedian advertised salary/yr (n=240)
Demand
The Skills Employers Ask For
What Life Sciences employers in Canada put in their job ads. The bar is how many postings ask for it; the arrow shows whether demand grew or shrank against the year before.
- phlebotomy290→
- blood samples185▲
- excel185▼
- outlook149▼
- word148▼
- specimens104▲
- venipuncture89▲
- laboratory specimens81→
- urine collection80▼
- data entry69→
What level are these roles?
Entry44
Intern11
Senior162
Lead64
Manager250
Most advertised titles
- 47
- 15
- 14
- 13
- 13
- 11
What Life Sciences research is working on
Aggregates 53,147 academic papers, of which 23,660 discuss opportunities, 4,958 identify common problems, and 1,880 issue cautions.
How this field talks about itself
Life Sciences papers (gold) against all published research (grey)
Descriptive40.2% · 17.6%2.3×
Promising30.4% · 37.2%0.8×
Breakthrough14.1% · 26.0%0.5×
Problem-identifying8.3% · 9.8%0.8×
Cautionary3.5% · 4.5%0.8×
Comparative2.4% · 3.8%0.6×
Life Sciences literature runs 2.3× more “descriptive” than science at large (40.2% vs 17.6% baseline).
How the work is done
Empirical48.8%
Reviews37.2%
Methods-led11.2%
Position pieces2.2%
Theoretical0.6%
How the research reads
80% positive · 16% neutral · 4% negative, across 53,147 papers.
The institutions behind the field
- 87k
- 75k
- 61k
- 49k
- 43k
- 38k
ranked by how often their work is cited
Researchers who shaped it
Ahmad Almilaji · Reiki Nishimura · Tomofumi Osako · Yasuyuki Nishiyama · Rumiko Tashima · Masahiro Nakano · Glenn R. Gibson · Gregor Reid
The most-cited breakthroughs
- Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity · 9k cites
- In situ click chemistry generation of cyclooxygenase-2 inhibitors · 8k cites
- U1 snRNP regulates cancer cell migration and invasion in vitro · 7k cites
- Comprehensive molecular profiling of lung adenocarcinoma · 6k cites
- Lanthanum Chloride Inhibits LPS Mediated Expressions of Pro-Inflammatory Cytokines and Adhesion Molecules in HUVECs: Involvement of NF-κB-Jmjd3 Signal · 6k cites
Common problems researchers identify4,503 papers · 7 recurring themes
Problems · theme 01
Sustainable Biofuel and Biomass Production
781 papers · 17.3% of this block
▲ +11% share2022→2025 share of research on this subject
Challenges in using microbes and plants for renewable fuels and biorefinery processes.
Biofuel · Synthetic biology · Biomass · Biorefinery
“A review on the plant microbiome: Ecology, functions, and emerging trends in microbial application”
781 of these papers raise it as a problem
Problems · theme 02
Food Safety and Processing Risks
757 papers · 16.8% of this block
▲ +41% share2022→2025 share of research on this subject
Issues surrounding microbial hazards, nutritional quality, and health impacts of processed foods.
Food safety · Food processing · Food products · Human health
“Microbial Risks in Food: Evaluation of Implementation of Food Safety Measures”
757 of these papers raise it as a problem
Problems · theme 03
Gene Expression and mRNA Therapeutics
711 papers · 15.8% of this block
▼ -31% share2022→2025 share of research on this subject
Barriers in controlling gene activity, mRNA delivery, and cell‑culture models for disease research.
Messenger RNA · Gene · Cell culture · Gene expression
“Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research”
711 of these papers raise it as a problem
Problems · theme 04
Crop Nutrition and Food Security
693 papers · 15.4% of this block
▲ +23% share2022→2025 share of research on this subject
Limitations in fertilizer use, nutrient uptake, and breeding strategies for resilient agriculture.
Agriculture · Crop · Food security · Germplasm
“Revisiting fertilisers and fertilisation strategies for improved nutrient uptake by plants”
693 of these papers raise it as a problem
Problems · theme 05
Plant Disease Management
691 papers · 15.3% of this block
▲ +35% share2022→2025 share of research on this subject
Complexities of fungicide resistance, host‑pathogen interactions, and integrated pest control.
Fungicide · Integrated pest management · Host · Disease management
“Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens”
691 of these papers raise it as a problem
Problems · theme 06
Antimicrobial Resistance Across Sectors
447 papers · 9.9% of this block
▲ +10% share2022→2025 share of research on this subject
Widespread emergence of drug‑resistant microbes in humans, livestock, and the environment.
Antibiotic resistance · Antimicrobial · Antibiotics · Drug resistance
“Antimicrobial resistance in humans, livestock and the wider environment”
447 of these papers raise it as a problem
Problems · theme 07
Miscellaneous Biological and Legal Topics
423 papers · 9.4% of this block
▼ -32% share2022→2025 share of research on this subject
Diverse, unrelated research areas lacking a clear thematic focus.
Order · NAD+ kinase · Human being · Sodium
“Modalidade, polaridade e legibilidade em resumos académicos: uma análise comparativa multidisciplinar”
423 of these papers raise it as a problem
Cautions1,765 papers · 7 recurring themes
Cautions · theme 01
Cellular Toxicity and Oxidative Stress
379 papers · 21.5% of this block
▼ -20% share2022→2025 share of research on this subject
Need for careful interpretation of in‑vitro and in‑vivo assays measuring stress responses.
In vivo · Flow cytometry · In vitro · Oxidative stress
“Effects of Microplastics on Cell Viability, Phagocytic Activity and Oxidative Stress in Human Peripheral Blood Mononuclear Cells”
379 of these papers raise it as a problem
Cautions · theme 02
Genomic Selection in Plant Breeding
257 papers · 14.6% of this block
▲ +25% share2022→2025 share of research on this subject
Caution about translating genomic predictions into practical crop improvement.
Agriculture · Selection · Production · Trait
“Genomic selection in plant breeding: from theory to practice”
257 of these papers raise it as a problem
Cautions · theme 03
Feed Additives and Animal Nutrition
245 papers · 13.9% of this block
▼ -17% share2022→2025 share of research on this subject
Potential unintended effects of novel feed compounds on animal health and sustainability.
Feed additive · Animal feed · Feed conversion ratio · Health benefits
“Natural Bioactive Compounds as Feed Additives: Strategies for Sustainable and Functional Livestock Production”
245 of these papers raise it as a problem
Cautions · theme 04
Food Contaminants and Regulatory Safety
240 papers · 13.6% of this block
▲ +14% share2022→2025 share of research on this subject
Risks associated with emerging food additives, contaminants, and their regulatory assessment.
Food safety · Hygiene · Contamination · Food contaminant
“Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters”
240 of these papers raise it as a problem
Cautions · theme 05
DNA Damage and Repair Mechanisms
239 papers · 13.5% of this block
▼ -32% share2022→2025 share of research on this subject
Uncertainties in interpreting gene‑expression changes linked to genomic instability.
Gene · DNA damage · DNA repair · Gene expression
“Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations”
239 of these papers raise it as a problem
Cautions · theme 06
Antibiotic Use and Co‑Selection Pressures
206 papers · 11.7% of this block
▲ +10% share2022→2025 share of research on this subject
Complex dynamics of resistance development when antibiotics mix with biocides or metals.
Antibiotic resistance · Antibiotics · Antimicrobial · Bacteria
“Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses”
206 of these papers raise it as a problem
Cautions · theme 07
Pesticide Resistance Management
199 papers · 11.3% of this block
▲ +16% share2022→2025 share of research on this subject
Challenges in designing dosing strategies that avoid resistance while maintaining efficacy.
Pesticide · Integrated pest management · PEST analysis · Biological pest control
“The use of fungal entomopathogens as endophytes in biological control: a review”
199 of these papers raise it as a problem
Opportunities22,038 papers · 7 recurring themes
Opportunities · theme 01
Advanced Antibody and Imaging Techniques
1,044 papers · 17.4% of this block
▼ -18% share2022→2025 share of research on this subject
Emerging platforms for in‑vivo labeling, fluorescence, and flow‑cytometry applications.
Antibody · In vivo · Fluorescence · Flow cytometry
“Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcom”
Opportunities · theme 02
Gene Regulation for Therapeutic Targets
1,032 papers · 17.2% of this block
▼ -26% share2022→2025 share of research on this subject
Promising approaches using knockdown, apoptosis control, and cell‑growth modulation.
Downregulation and upregulation · Apoptosis · Gene knockdown · Cell growth
“Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing <sc”
Opportunities · theme 03
Functional Plant‑Based Foods
878 papers · 14.6% of this block
▲ +68% share2022→2025 share of research on this subject
Development of antioxidant‑rich ingredients and health‑promoting food products.
Health benefits · Functional food · Ingredient · Antioxidant
“Plant-based functional foods for healthy aging: current trends, bioactive compounds, and future perspectives”
Opportunities · theme 04
Epigenetic and RNA‑Based Diagnostics
823 papers · 13.7% of this block
▼ -32% share2022→2025 share of research on this subject
Innovations in DNA methylation profiling and miRNA detection for disease monitoring.
Gene · DNA methylation · Messenger RNA · DNA damage
“Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders”
Opportunities · theme 05
Novel Antimicrobials and Biocontrol Agents
809 papers · 13.5% of this block
▲ +25% share2022→2025 share of research on this subject
Exploration of plant‑derived compounds and postbiotic products to combat resistance.
Antimicrobial · Antibiotic resistance · Biological pest control · Bacteria
“Plants as sources of new antimicrobials and resistance-modifying agents”
Opportunities · theme 06
Genetic Improvement of Germplasm
717 papers · 11.9% of this block
▼ -22% share2022→2025 share of research on this subject
Leveraging quantitative trait loci and selection to boost crop yields and traits.
Germplasm · Trait · Quantitative trait locus · Selection
“Evaluation of Genetic Variability and Trait Interrelationships Using Advanced Wheat Lines to Increase Yield”
Opportunities · theme 07
Sustainable Biomass and Biofuel Strategies
697 papers · 11.6% of this block
▲ +29% share2022→2025 share of research on this subject
Utilizing microbial fermentation and agri‑food by‑products for greener energy and materials.
Biomass · Sustainability · Agriculture · Biofuel
“Microbial Fermentation: A Sustainable Strategy for Producing High-Value Bioactive Compounds for Agriculture, Animal Feed, and Human Health”
Which of these themes are growing fastest
Problems
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Food Safety and Processing Risks▲+41%
Plant Disease Management▲+35%
Crop Nutrition and Food Security▲+23%
Sustainable Biofuel and Biomass Production▲+11%
Antimicrobial Resistance Across Sectors▲+10%
Gene Expression and mRNA Therapeutics▼-31%
Miscellaneous Biological and Legal Topics▼-32%
Cautions
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Genomic Selection in Plant Breeding▲+25%
Pesticide Resistance Management▲+16%
Food Contaminants and Regulatory Safety▲+14%
Antibiotic Use and Co‑Selection Pressures▲+10%
Feed Additives and Animal Nutrition▼-17%
Cellular Toxicity and Oxidative Stress▼-20%
DNA Damage and Repair Mechanisms▼-32%
Opportunities
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Functional Plant‑Based Foods▲+68%
Sustainable Biomass and Biofuel Strategies▲+29%
Novel Antimicrobials and Biocontrol Agents▲+25%
Advanced Antibody and Imaging Techniques▼-18%
Genetic Improvement of Germplasm▼-22%
Gene Regulation for Therapeutic Targets▼-26%
Epigenetic and RNA‑Based Diagnostics▼-32%
Prism
Go deeper on Life Sciences research and innovation
Research themes, patent activity and the companies commercialising them, in one place.
Keep going
Track Life Sciences in Canada beyond this page
Radar finds and filters the companies. Prism watches what is being said about them.
About this data: built from Fliar's company, founder, funding, hiring, jobs, news and research trackers, covering Canada. Counts are of companies we track, not of every company that exists. Updated August 2026.
Contact details
Reach this founder through Fliar Radar
Direct contact details for the people on this page are held in Fliar Radar, behind its own access controls.